Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03611699 · ClinicalTrials.gov registry record · Phase 4

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

A Phase 4 study of COPD, sponsored by Gary L. Pierce.

Completed
Registry status
Phase 4
Development phase
15
Enrollment target
1
Study location

NCT03611699: Completed Phase 4 study of COPD, sponsored by Gary L. Pierce.

NCT03611699 is a Phase 4 study of COPD that has completed, run by Gary L. Pierce. The registered enrollment target is 15 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03611699, a Phase 4 study of COPD, has completed, sponsored by Gary L. Pierce.

COMPLETED
Registry status
Phase 4
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to evaluate the acute effects of a long-acting bronchodilator on pulmonary function, vascular function and muscle sympathetic nerve activity in individuals with COPD. Individuals will be recruited from previous pulmonary research cohorts at The University of Iowa hospitals and clinics. Individuals that are interested in the study and are deemed eligible to participate will have a total of 3 visits to the laboratory, which includes the screening and consent (visit 1) that will last approximately 1 hour. Visits 2 and 3 are experimental visits and will be more extensive (\~4 hours). Participants will be randomized to receive either a long-acting bronchodilator or a placebo inhaler at the first experimental visit, followed by either the placebo inhaler or the long-acting bronchodilator at the second experimental visit. Assessments of pulmonary function, vascular function (via non-invasive, well-established techniques), and muscle sympathetic nerve activity will be performed at both experimental visits.

Primary Outcome

Carotid artery stiffness as determined by carotid sonography

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Umeclidinium / Vilanterol Dry Powder Inhaler

Study Locations (1)

Iowa

  • The University of Iowa Hospital and Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-01-24
Est. Completion 2020-04-01
Phase Phase 4
Gary L. Pierce

4 total trials

What the finished NCT03611699 record still lists

NCT03611699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower).

The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03611699 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT03611699 about?

NCT03611699 is a clinical study titled "Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients". The goal of this study is to evaluate the acute effects of a long-acting bronchodilator on pulmonary function, vascular function and muscle sympathetic nerve activity in individuals with COPD. Individuals will be recruited from previous pulmonary research cohorts at The University of Iowa hospitals ...

What is the current status of trial NCT03611699?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2019-01-24. Estimated completion is 2020-04-01.

What conditions does trial NCT03611699 study?

This clinical trial studies the following conditions: COPD.

What interventions are being tested in trial NCT03611699?

The interventions under investigation include: Placebo (DRUG), Umeclidinium / Vilanterol Dry Powder Inhaler (DRUG).

Who is sponsoring clinical trial NCT03611699?

This trial is sponsored by Gary L. Pierce, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03611699 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03611699's enrollment target sits among peer trials

15 79th of 85 higher than 7 of 85 other COPD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03611699, the US trial registry maintained by the National Library of Medicine. NCT03611699 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.